| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/16/2001 | CA2062933C Novel process for the preparation of 9-deoxo-9(z)-hydroxyiminoerythromycin a |
| 01/16/2001 | CA2052615C Pharmaceutical composition in gel form in a dispensing package |
| 01/16/2001 | CA2021954C Substituted triazolinones, triazolinethiones and triazolinimines as angiotensin ii antagonists |
| 01/16/2001 | CA2018818C Treatment of postmenopausal disorders |
| 01/16/2001 | CA1341166C Antigenic proteins and vaccines containing them for prevention of coccidiosis |
| 01/14/2001 | CA2277407A1 Pharmaceutical tablet comprising an nsaid and misoprostol |
| 01/13/2001 | CA2277564A1 Inhibiting agent against platelet-derived growth factor increase and arteriosclerosis preventive and therapeutic agent |
| 01/12/2001 | CA2307086A1 Skin care composition |
| 01/11/2001 | WO2001003325A2 Use of creatine and/or creatine derivatives for treating feelings of ill-health in women |
| 01/11/2001 | WO2001002601A2 Cell-based assay systems for examining hcv ns3 protease activity |
| 01/11/2001 | WO2001002593A2 Control of gene expression in eukaryotic cells |
| 01/11/2001 | WO2001002568A2 Human genes and gene expression products |
| 01/11/2001 | WO2001002561A2 Mammalian calcium channels and related probes, cell lines and methods |
| 01/11/2001 | WO2001002560A1 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 01/11/2001 | WO2001002559A1 Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| 01/11/2001 | WO2001002557A1 Neurotrophic factor receptor |
| 01/11/2001 | WO2001002550A2 Cell death related drug targets in yeast and fungi |
| 01/11/2001 | WO2001002443A1 Heparin compositions that inhibit clot associated coagulation factors |
| 01/11/2001 | WO2001002426A1 A substantially crystalline form of melagatran |
| 01/11/2001 | WO2001002424A2 Peptide boronic acid inhibitors of hepatitis c virus protease |
| 01/11/2001 | WO2001002423A2 2'-guanidinyl-substituted oligonucleotides and gene expression modulation therewith |
| 01/11/2001 | WO2001002417A1 Nucleotide monomer containing six-membered azarsugar and antisense oligomers thereof |
| 01/11/2001 | WO2001002414A1 Diphosphate salt of a 4''-substituted-9-deoxo-9a-aza-9a-homoerythromycin derivative and its pharmaceutical composition |
| 01/11/2001 | WO2001002413A1 BAFIlOMYCIN DERIVATIVES WITH ANTICANCER ACTIVITY |
| 01/11/2001 | WO2001002411A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF β-LACTAMASE |
| 01/11/2001 | WO2001002410A1 Novel process |
| 01/11/2001 | WO2001002409A1 Thieno- and furopyrimidine derivatives as a2a-receptor antagonists |
| 01/11/2001 | WO2001002408A1 Novel xanthone compounds, their preparation and use as medicament |
| 01/11/2001 | WO2001002407A2 Taxane derivatives and processes for the preparation thereof |
| 01/11/2001 | WO2001002406A1 Potassium channel blocking agents |
| 01/11/2001 | WO2001002405A1 Quinuclidine derivatives for treatment of neurological disorders |
| 01/11/2001 | WO2001002403A1 METHOD FOR PREPARING SUBSTITUTED [1,4]DIAZEPINO[6,7,1-hi]INDOL-4-ONES |
| 01/11/2001 | WO2001002401A1 Crystalline 1-methylcarbapenem compounds |
| 01/11/2001 | WO2001002399A1 Substituted purine derivatives as inhibitors of cell adhesion |
| 01/11/2001 | WO2001002398A1 Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them |
| 01/11/2001 | WO2001002396A1 Novel benzo[f]naphthyridine, preparation and compositions containing them |
| 01/11/2001 | WO2001002394A1 Substituted indole compounds and their use for the treatment of cancer |
| 01/11/2001 | WO2001002393A1 Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives |
| 01/11/2001 | WO2001002392A1 Heterocyclic aminopyrrolidine derivatives as melatonergic agents |
| 01/11/2001 | WO2001002391A2 Bicyclic aromatic compounds for treating drug addiction |
| 01/11/2001 | WO2001002390A1 Quinolinecarboxylic acid derivative or salts thereof |
| 01/11/2001 | WO2001002389A1 Crystals of benzimidazole compounds |
| 01/11/2001 | WO2001002388A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 01/11/2001 | WO2001002387A1 N-imidazolylmethyl carboxamides as nitric oxide production inhibitors |
| 01/11/2001 | WO2001002381A1 Piperazine derivatives as modulators of chemokine receptor activity |
| 01/11/2001 | WO2001002380A1 Antipsychotic cyclic n-aralkyl amines |
| 01/11/2001 | WO2001002379A1 Selective npy (y5) antagonists |
| 01/11/2001 | WO2001002377A1 Telomerase inhibitors and methods of their use |
| 01/11/2001 | WO2001002376A1 Amino-alkyl derivatives |
| 01/11/2001 | WO2001002373A1 Dihydrobenzodiazepins and their use for treating dyslipidemia |
| 01/11/2001 | WO2001002372A1 Cyclized amino acid derivatives |
| 01/11/2001 | WO2001002369A2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| 01/11/2001 | WO2001002368A1 N-heterocyclic derivatives with neuronal activity |
| 01/11/2001 | WO2001002366A2 Substituted isoquinoline derivatives and their use as inticonvulsants |
| 01/11/2001 | WO2001002363A2 N-substituted glycine derivatives |
| 01/11/2001 | WO2001002362A1 Azo amino acid derivatives for the treatment of neurological diseases |
| 01/11/2001 | WO2001002361A1 Beta-amino acid derivatives for the treatment of neurological diseases |
| 01/11/2001 | WO2001002360A1 Process for preparing amlodipine benzenesulphonate |
| 01/11/2001 | WO2001002358A2 Cyclized amide derivatives for treating or preventing neuronal damage |
| 01/11/2001 | WO2001002349A1 Phenyl sulfamate derivatives |
| 01/11/2001 | WO2001002018A2 Compounds that associate on the intermolecular level and aggregate bodies that contain them |
| 01/11/2001 | WO2001002016A1 Nasogastric enteral formulations |
| 01/11/2001 | WO2001002015A1 Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs |
| 01/11/2001 | WO2001002014A1 Medicinal compositions for treating colorectal cancer |
| 01/11/2001 | WO2001002004A1 Peritoneal dialysis solution containing antioxidant for treating renal failure |
| 01/11/2001 | WO2001001999A1 Method of inducing apoptosis in b-lymphocytes |
| 01/11/2001 | WO2001001998A2 Treatment of endometriosis with antileukoprotease |
| 01/11/2001 | WO2001001995A2 Method for treatment of asthma syndrome |
| 01/11/2001 | WO2001001991A1 Pharmaceutical tablets |
| 01/11/2001 | WO2001001990A1 Adhesive preparation for percutaneous absorption |
| 01/11/2001 | WO2001001989A1 Novel pharmaceutical combination with analgesic action containing paracetamol and buspirone |
| 01/11/2001 | WO2001001988A1 Compounds having cytokine inhibitory activity |
| 01/11/2001 | WO2001001987A1 Use of an angiotensin ii type 1 receptor antagonist in the manufacture of a medicament for the treatment of cardiovascular complications |
| 01/11/2001 | WO2001001986A1 Method of reducing neuronal injury or apoptosis |
| 01/11/2001 | WO2001001985A1 Antiviral therapy |
| 01/11/2001 | WO2001001984A1 Levodopa / carbidopa / entacapone pharmaceutical preparation |
| 01/11/2001 | WO2001001983A1 A synergistic combination: gabapentin and pregabalin |
| 01/11/2001 | WO2001001982A1 Aminoethanesulfonic acid-containing preparations |
| 01/11/2001 | WO2001001981A1 Vegf receptor antagonists |
| 01/11/2001 | WO2001001980A1 Methods for the amelioration of neuropsychiatric disorders by inhibiting the inactivating transport of endogenous cannabinoid substances |
| 01/11/2001 | WO2001001979A1 Therapeutic agents |
| 01/11/2001 | WO2001001978A1 Medicinal compositions for preventing or treating viral myocarditis |
| 01/11/2001 | WO2001001977A1 Methods for controlling fungal pathogens |
| 01/11/2001 | WO2001001975A2 Hypoestoxides, derivatives and agonists thereof for use as antiparasitic agents |
| 01/11/2001 | WO2001001974A2 Naaladase inhibitors in anxiety and memory disorders |
| 01/11/2001 | WO2001001973A2 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 01/11/2001 | WO2001001972A2 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 01/11/2001 | WO2001001971A1 Use of cortisol antagonists in the treatment for heat failure |
| 01/11/2001 | WO2001001970A2 New uses potassium channel openers, such as the treatment of epilepsy |
| 01/11/2001 | WO2001001969A2 Methods of treating and/or suppressing weight gain |
| 01/11/2001 | WO2001001968A2 Methods and compositions for regulating gut motility and food intake |
| 01/11/2001 | WO2001001963A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | WO2001001962A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | WO2001001961A1 Oral micro-emulsion composition of silybin |
| 01/11/2001 | WO2001001958A1 Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip |
| 01/11/2001 | WO2001001956A2 Solid preparations containing paroxetine |
| 01/11/2001 | WO2001001955A1 Nasal formulation of an antifungal |
| 01/11/2001 | WO2001001947A1 Cosmetic skin care compositions containing cumic alcohol |
| 01/11/2001 | WO2001001939A1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 01/11/2001 | WO2001001932A2 Oligosaccharide aldonic acids and their topical use |